br1

BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes.

TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).

TGFBR1-IN-2 (Compound AQA) is a TGFBR1 inhibitor (KD: 0.01 μM) and antimicrobial agent. It serves as a substrate for cytochrome P450. The compound contains a pyridyl-6-methyl group, essential for inhibiting Mycobacterium tuberculosis, and effectively inhibits non-replicating and persistent strains of this bacterium.

BR103354 is a novel fibroblast activation protein (FAP) inhibitor with anti-diabetic and anti-steatotic effects. BR103354 inhibited FAP with an IC50 value of 14 nM, showing high selectivity against dipeptidyl peptidase (DPP)-related enzymes and prolyl oligopeptidase (PREP). BR103354 exhibited good pharmacokinetic properties as evidenced by oral bioavailability of 48.4% and minimal hERG inhibition. Single co-administration of BR103354 with hFGF21 reduced nonfasting blood glucose concentrations, in association with increased intact form of hFGF21 in ob ob mice. BR103354 acts as an effective FAP inhibitor in vitro and in vivo, thereby demonstrating its potential application as an anti-diabetic and anti-NASH agent.

BR103 is a C3aR-selective agonist that is metabolically stable.

NIBR189 is a potent and selective antagonist of EBI2 (GPR183) receptor (IC50 of 11 and 15 nM for human and mouse EBI2 receptors, respectively)

CBR1-IN-3 (compound 13h) serves as a potent inhibitor of carbonyl reductase 1 (CBR1), exhibiting an IC 50 value of 0.034 μM [1].

CBR1-IN-4 (Compound 13p), with an IC50 value of 0.09 μM, acts as an inhibitor of human carbonyl reductase 1 (CBR1). This compound is applicable in cancer research [1].

CBR1-IN-5 (compound 13o) effectively inhibits CBR1, exhibiting an IC 50 value of 0.1 μM [1].

CBR1-IN-7 (Compound JV-2), with an IC50 value of 8 μM, serves as an inhibitor of human CBR1. This compound finds utility in cancer research [1].

BR102910 (4-Thiazolecarboxamide, N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidinyl]-2-oxoethyl]-2-[(3,4-dichlorophenyl)methyl]-) is a selective inhibitor of fibroblast activated protein (FAP).

PRL-3 Inhibitor I (BR-1) is a phosphatase of regenerating liver 3 (PRL-3) inhibitor which blocks the migration and invasion of metastatic cancer cells.